Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cotinga Pharmaceuticals Inc COTQF

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.


GREY:COTQF - Post by User

Comment by DIYGuyon Dec 15, 2017 7:34am
74 Views
Post# 27162634

RE:Even if we get positive result we will need a lot of $$$$

RE:Even if we get positive result we will need a lot of $$$$I don’t see any issue with raising capital if you are getting positive results and they are progressing through the clinical trials. The problem is waiting too long and looking for money when you are running out. Then you are at their mercy.

If we get positive results and the combination trial starts who knows maybe we move back above $2 and then we get 2MM from the exercise of the special warrants.

Looking way ahead I would expect a partnership with big pharma for phase 3 of a clinical trial, but at this point that may be wishful thinking.

Hoping for good news next week before the annual meeting. The real excitement for me will be the COTI-2 + radiation combination trial.  If you look at the preclinical results in 4/7th of the cases the results were outstanding. 65,0000 people in the US diagnosed with HNSCC each year and about 50% have p53 mutation.

my 2 cents
<< Previous
Bullboard Posts
Next >>